<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727883</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OIT-DUM-2006/1</org_study_id>
    <nct_id>NCT00727883</nct_id>
  </id_info>
  <brief_title>Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients</brief_title>
  <acronym>SOSTA</acronym>
  <official_title>Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational trial on reasons for withdraw of Adjuvant Tamoxifen in Breast
      Cancer patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of withdraw from adjuvant Tamoxifen due to Tam related AEs</measure>
    <time_frame>January 2003-December 2004</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Types of TAM related AE</measure>
    <time_frame>January 2003-December 2004</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">190</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Post menopausal women treated with adjuvant TAM for breast cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Post menopausal women treated with adjuvant TAM for breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast Ca Patients with surgery and withdraw of adjuvant treatment with Tamoxifen for
             Tam related AEs

          -  Documented reasons for treatment withdrawal

        Exclusion Criteria:

          -  enrollment in other studies

          -  treatment withdraw for other causes than Tam related AEs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2008</study_first_posted>
  <last_update_submitted>December 9, 2010</last_update_submitted>
  <last_update_submitted_qc>December 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Davide Meani Specialty Medical Affairs Manager</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Adjuvant TAM</keyword>
  <keyword>post-menopausal</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

